QNCX Quince Therapeutics: Price-to-Projected Revenue Ratio

Quince Therapeutics, Inc. - graphic logo of issuer QNCX

Quince Therapeutics (QNCX) integrates ESG standards into the development of metabolic drugs while adhering to strict bioethics. The company is developing the AOC platform for erythrocyte-mediated drug delivery to reduce therapy toxicity. The estimated forward P/S reflects the business valuation relative to expected revenues, where the value serves as the current metric. The operating model relies on a virtual structure with full production outsourcing.

Quince Therapeutics Inc - QNCX Market Cap to Expected Sales Ratio (period 07/04/2022 - 11/17/2026)

Summary analytical data breakdowns for Quince Therapeutics Inc (QNCX)

Basic company analysis:Quince Therapeutics (QNCX)
Original product of Quince Therapeutics, Inc.

For Quince Therapeutics (QNCX), whose success depends on the clinical trial results of drug delivery systems, the forward price-to-sales ratio reflects market expectations for the future commercialization of molecules. This indicator is calculated as the ratio of current market capitalization to projected sales, allowing investors to assess the premium paid for future growth and determine whether the asset's current valuation is justified or speculative.

Competitors of Quince Therapeutics

Price-to-Projected Revenue Ratio ascendispharma.com ASND|Madrigal Corp (MDGL) - Market Cap to Future Revenue Ratio|CORT - Price-to-Projected Revenue Ratio|RYTM: Price-to-Projected Revenue Ratio|AKRO: Forward P/S Multiple|MTSR - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio MoonLake Corp|Crinetics Corp (CRNX) - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio newamsterdampharma.com (NAMS)|Forward Price-to-Revenue Multiple soleno.life SLNO|Forward P/S Multiple FOLD (amicusrx.com)|Market Cap to Expected Sales Ratio 89bio (ETNB)|Agios - Forward P/S Multiple|Structure Corp - Price to Expected Revenue Ratio|mimedx.com (MDXG) - Price-to-Projected Revenue Ratio|Future Price to Revenue RZLT (rezolutebio.com)|LXRX (Lexicon Pharmaceuticals Inc) - Forward P/S Multiple|Price-to-Projected Revenue Ratio MBX|Price-to-Projected Revenue Ratio Altimmune Pharma (ALT)|Price-to-Projected Revenue Ratio AARD (Aardvark Therapeutics Corp)|Forward P/S Multiple SGMT (Sagimet Biosciences, Inc.)|BioAge (BIOA) - Market Cap to Future Revenue Ratio|BMEA: Forward Price-to-Revenue Multiple|GUTS: Price-to-Projected Revenue Ratio|vTv Therapeutics Inc (VTVT) - Price-to-Projected Revenue Ratio|ATPC: Price to Expected Revenue Ratio|PLUR (pluri-biotech.com) - Forward P/S Multiple|SYBX: Forward Price to Sales|Forward P/S Multiple LPCN|Market Cap to Expected Sales Ratio Matinas BioPharma Holdings, Inc.|Price-to-Projected Revenue Ratio Spruce Biosciences Inc. SPRB|GLTO - Forward Price-to-Revenue Multiple|CTCX - Price-to-Projected Revenue Ratio|LUMO - Forward P/S Multiple|ONVO: Forward P/S Multiple|RDUS (Radius Recycling) - Price-to-Projected Revenue Ratio